22.07 15:30
30 Min
Medical Frontiers: 2050-139
A new drug jointly developed by Japanese and US pharmaceutical companies targets HER2-positive breast cancers - in a clinical study, cancer shrank or disappeared in 60 per cent of subjects. (NHK WORLD-JPN)
22.07 21:30
30 Min
Medical Frontiers: 2050-139
A new drug jointly developed by Japanese and US pharmaceutical companies targets HER2-positive breast cancers - in a clinical study, cancer shrank or disappeared in 60 per cent of subjects. (NHK WORLD-JPN)
23.07 04:30
30 Min
Medical Frontiers: 2050-139
A new drug jointly developed by Japanese and US pharmaceutical companies targets HER2-positive breast cancers - in a clinical study, cancer shrank or disappeared in 60 per cent of subjects. (NHK WORLD-JPN)
23.07 10:30
30 Min
Medical Frontiers: 2050-139
A new drug jointly developed by Japanese and US pharmaceutical companies targets HER2-positive breast cancers - in a clinical study, cancer shrank or disappeared in 60 per cent of subjects. (NHK WORLD-JPN)
26.07 20:00
30 Min
Medical Frontiers: 2050-139
A new drug jointly developed by Japanese and US pharmaceutical companies targets HER2-positive breast cancers - in a clinical study, cancer shrank or disappeared in 60 per cent of subjects. (NHK WORLD-JPN)